Focus on NSCLC
Lung Cancer Resource Center
Focus on NSCLC
Featured Content
FDA Approves Cemiplimab-Rwlc for First-Line Advanced NSCLC
The FDA recently approved the PD-1 inhibitor cemiplimab-rwlc for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score ≥50%), as determined by an FDA-approved test.
Analyzing Real-World Data Results: Pembrolizumab in Metastatic NSCLC
A study of real-world data suggests that patients with metastatic non-small cell lung cancer (NSCLC) who received pembrolizumab in combination with chemotherapy are more likely to remain on therapy past 90 days compared to those who received chemotherapy alone.
Understanding Socioeconomic Disparities in Lung Cancer Care
A recent study found that sociodemographic factors such as race, marital, income, and insurance status are associated with disparities in the receipt of lung cancer treatment, according to findings presented at the NCCN 2021 Virtual Annual Conference (Abstract EPR21-039).
Significant Variation Found in Timing & Selection of Genetic Tests for NSCLC
Biomarker testing surveys specific disease-associated molecules to predict treatment response and disease progression; however, its use has complicated the diagnosis of non-small cell lung cancer (NSCLC).
Loading